A clot-busting drug recently approved to treat acute ischemic strokes (AIS) that can be delivered quickly works as well as a ...

SGLT2 inhibitors vs placebo were associated with reduced heart failure hospitalization among patients with history of myocardial infarction.

A new review published in Genes & Diseases highlights macrophage-targeted therapy as a promising frontier in cardiac regeneration and myocardial repair.

Dr. Ayo presents his final in the series of Heart and Stroke month preventative care tips in Part 6 during Heart and Stroke awareness ...

The following is a summary of "Low-dose dobutamine stress myocardial contrast echocardiography for evaluating myocardial ...

Composite of coronary heart disease death and non-fatal myocardial infarction was less frequent in the CCTA group compared to ...

For over two decades, a ‘treatment-risk paradox’ has been described in older adults with cardiovascular disease, with ...

The FDA has approved TNKase, a new, fast-acting stroke treatment that dissolves blood clots more efficiently, marking a significant advancement in stroke therapy and clot-busting technology.

Genentech has had the lone medicine on the market for the acute treatment of stroke. | Over nearly the last three decades, ...

Researchers have observed that female patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) are more likely to ...

The following is a summary of "Impact of sodium-glucose cotransporter‐2 inhibitors in patients with recent versus previous ...